LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.25
3.25
Intervallo Annuale
1.81
5.06
Variazione giornaliera
-1.81%
Variazione Mensile
+1.25%
Variazione di 6 mesi
+58.54%
Variazione Annuale
+16.49%
Chiusura Precedente
3.3 1
Open
3.2 5
Minimo
3.2 5
High
3.2 5
Volume
4
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore 20202021202220232024 TTM

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Notizie